SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

NCT ID: NCT01329289

Last Updated: 2016-02-12

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-12-31
• Study Completion Date: 2012-02-29

Brief Summary

The purpose of this study is to determine if adding SOM230 LAR to bortezomib and dexamethasone is better than bortezomib and dexamethasone alone and if it should be investigated further.

Conditions

Multiple Myeloma in Relapse; Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SOM230 with Bortezomib and Dexamethasone

Group Type: EXPERIMENTAL

SOM230

Intervention Type: DRUG

60 mg intramuscularly (IM) on day 1 of each 28 day cycle

Bortezomib

Intervention Type: DRUG

1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.

Dexamethasone

Intervention Type: DRUG

20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).

Interventions

SOM230

60 mg intramuscularly (IM) on day 1 of each 28 day cycle

Intervention Type: DRUG

Bortezomib

1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.

Intervention Type: DRUG

Dexamethasone

20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).

Intervention Type: DRUG

Other Intervention Names

Pasireotide; Velcade; Decadron; Dexasone; Diodex; Hexadrol; Maxidex; dexamethasone sodium phosphate; dexamethasone acetate

Eligibility Criteria

Inclusion Criteria

• Patients must have histologically or cytologically confirmed symptomatic MM, Salmon-Durie Stage II or III, International Staging System II or III, or fulfill the CRAB criteria (see Appendix A, B). Patients should have previously been treated with at least one cycle of bortezomib, after which the patient has shown progressive or refractory disease. Finally, patients must meet at least one of the following parameters of measurable disease:

• Bone marrow plasmacytosis with> 10% plasma cells, or sheets of plasma cells, or biopsy proven plasmacytoma which must be obtained within 6 weeks prior to registration.
• Measurable levels of monoclonal protein (M-protein): ≥ 1 g/dL on serum protein electrophoresis (SPEP) or ≥ 200 mg of monoclonal light chain on a 24 hour urine protein electrophoresis (UPEP) or involved FLC ≥ mg/dL (≥ 100 mg/L) which must be obtained within 4 weeks prior to registration.
• Serum and urine M-protein levels should be determined by electrophoresis rather than by quantitative immunoglobulin (Ig) measurement. Exceptions are made in cases in which the M-spike value may be deemed to be unreliable ( e.g. co-migrating M-spike). In these cases, quantitative Ig should be used. To assess response and progression, however, SPEP values should only be compared to SPEP values and quantitative Ig values only to quantitative Ig values.
• Patients must have received at least two prior anti-MM treatments. The prior treatments must include at least one IMiD (thalidomide or lenalidomide) and bortezomib. If patients are unable to tolerate thalidomide or lenalidomide they can be included without prior IMiD treatment. Patients may be included if they did not experience grade III neuropathy while on bortezomib. Patients may have previously received autologous or peripheral blood stem cell transplantation.
• Minimum of four weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy. Exception: e.g. kyphoplasty, vertebroplasty, local radiation therapy for symptomatic bone lesions (e.g., uncontrolled pain or high risk of pathologic fracture).
• Age ≥ 18 years.
• Life expectancy of greater than 12 weeks.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%; see Appendix B).
• Patients must have adequate organ and marrow function as defined below, obtained within 4 weeks prior to registration:

• Hgb > 9 g/dL (which may be supported by transfusion or growth factors)
• Absolute neutrophil count > 1000 x 10-9/L
• Platelets ≥ 50,000 x 10-9/L
• PT/PTT < 1.5 x upper limits of normal (ULN)
• Total bilirubin ≤ 1.5 x (ULN)
• Hepatic:

Serum bilirubin ≤ 1.5 ULN

Aspartate aminotransferase and alanine aminotransferase

• 3 × ULN without liver metastases
• 5 × ULN if documented liver infiltration

• Renal:

Calculated creatinine clearance ≥40 ml/min according to the formula in Appendix D

• Cholesterol* ≤ 300 mg/dL
• Triglycerides (fasting)* ≤ 2.5 x ULN
• Fasting plasma glucose (FPG)** < 1.5X ULN for FPG or HbA1c ≤ 8% *In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.

At the principle investigator's discretion, non-eligible patients can be re-screened after adequate medical therapy has been instituted.

• Patients must not be pregnant or breast feeding and must have a negative pregnancy test within 14 days of the administration of the first study treatment. Further, all women of childbearing potential and sexually active males must agree to use a medically effective contraception method throughout the treatment period and avoid conception while participating in this study. Women must not be lactating. Post menopausal patients and patients who had a bilateral oophorectomy need not take a pregnancy test.
• Ability to understand and the willingness to sign a written informed consent document. Patient must be informed of the investigational nature of this study.
• Patient should be able to swallow pills

Exclusion Criteria

• Patients who have had chemotherapy, radiotherapy, or major surgery within 4 weeks prior to entering the study or those who have not recovered from AEs due to chemotherapy, radiotherapy, or major surgery completed more than 4 weeks prior to registration. Exception: local radiation therapy for symptomatic bone lesions (e.g., uncontrolled pain or high risk of pathologic fracture).
• Patients with any of the following cardiac abnormalities:

• QTcF at screening > 450 msec
• History of syncope or family history of idiopathic sudden death
• Sustained or clinically significant cardiac arrhythmias
• Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade AV block
• Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure
• Concomitant medication(s) known to increase the QT interval
• Diabetic patients on antidiabetic medications whose HbA1C > 8%
• Patients currently receiving high dose systemic steroids for treatment of MM, patients without prior bortezomib treatment, patients who received an investigational agent within 5 half lives of the agent.
• Patients who require therapeutic (full) anticoagulation such as full dose low molecular weight heparin or Coumadin with a goal INR of 2-3.
• Patients with known brain metastases (treated or not) will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other AEs.
• Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to SOM230 LAR and/or bortezomib or other agents used in the study.
• Patients should not receive immunization with attenuated live vaccines during study period or within 1 week of study entry.
• Patients with symptomatic cholelithiasis.
• Patients previously treated with sst or sst analogues.
• Patients with a second malignancy other than squamous/basal cell carcinoma of the skin or in situ carcinoma of the cervix unless the tumor was curatively treated.
• Known HIV infection
• Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:

• Severely impaired lung function
• Any active (acute or chronic) uncontrolled disorders
• Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the study therapy
• Women who are pregnant or breast feeding, or women/men able to conceive and unwilling to practice a medically effective method of birth control.
• Inability to comply with study and/or follow-up procedures or history of medical noncompliance.
• Patients who have a serious cardiac condition, such as myocardial infarction within 6 months, unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, history of syncope, family history of idiopathic sudden death, QTc > 450 msec, advanced heart block or heart disease as defined by the New York Heart Association Class III or IV. (See ECG guidelines, Section 8.0).
• Patients with non-secretory MM.
• Patients with prior allogeneic transplantation.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: collaborator

University of Pittsburgh

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Countries

United States

Other Identifiers

10-078

Identifier Type: -

Identifier Source: org_study_id